Pfizer-Valneva Lyme Vaccine Shows 73% Efficacy but Misses Statistical Endpoint

Pfizer and Valneva's Phase 3 Lyme disease vaccine trial reduced cases by about 73%, yet it failed to meet its primary statistical endpoint due to the confidence interval missing the threshold. This outcome complicates regulatory approval despite promising efficacy and safety signals, reflecting challenges in vaccine evaluation. The companies plan to pursue regulatory review, which will determine if the vaccine can move closer to public use against Lyme disease affecting hundreds of thousands annually.